Jennifer Arney
Overview
Explore the profile of Jennifer Arney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naik A, Shanahan M, Dindo L, Mecca M, Arney J, Amspoker A, et al.
Contemp Clin Trials
. 2024 Jun;
143:107613.
PMID: 38914308
Background: Providing healthcare for older adults with multiple chronic conditions (MCC) is challenging. Polypharmacy and complex treatment plans can lead to high treatment burden and risk for adverse events. For...
2.
Smith A, Touchett H, Chen P, Fletcher T, Arney J, Hogan J, et al.
JMIR Ment Health
. 2024 Feb;
11:e50977.
PMID: 38306167
Background: Technology-based mental health interventions address barriers rural veterans face in accessing care, including provider scarcity and distance from the hospital or clinic. webSTAIR is a 10-module, web-based treatment based...
3.
Arney J, Gregg L, Wydermyer S, Herrera M, Richardson P, Matheny M, et al.
Cardiorenal Med
. 2023 Dec;
14(1):34-44.
PMID: 38151011
Introduction: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) improve outcomes but are underutilized in patients with chronic kidney disease (CKD). Little is known about reasons for discontinuation and...
4.
Gregg L, Richardson P, Herrera M, Akeroyd J, Jafry S, Gobbel G, et al.
Am J Nephrol
. 2023 May;
54(3-4):126-135.
PMID: 37231800
Introduction: Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) are frequently discontinued in patients with chronic kidney disease (CKD). Documented adverse drug reactions (ADRs) in medical records may provide...
5.
Dayton R, Fonner V, Plourde K, Sanyal A, Arney J, Orr T, et al.
AIDS Behav
. 2023 Apr;
27(10):3223-3238.
PMID: 37119401
Adolescent girls and young women (AGYW) are disproportionately affected by HIV, and oral pre-exposure prophylaxis (PrEP) can reduce HIV acquisition. The purpose of this scoping review was to synthesize results...
6.
Arney J, Gray C, Walling A, Clark J, Smith D, Melcher J, et al.
BMJ Open
. 2023 Jan;
12(9):e062836.
PMID: 36691142
Objectives: The purpose of this paper is to present two divergent mental models of integrated advanced liver disease (AdvLD) care among 26 providers who treat patients with AdvLD. Setting: 3...
7.
Gray C, Arney J, Clark J, Walling A, Kanwal F, Naik A
Soc Sci Med
. 2022 Jun;
305:115113.
PMID: 35690034
Advanced liver disease is often uncurable and fatal. Liver transplant is the only curative option for patients with advanced, irreversible liver disease, but the need for new livers far exceeds...
8.
Samper-Ternent R, Tinetti M, Jennings L, Wong R, Arney J, Naik A
J Am Geriatr Soc
. 2022 Mar;
70(6):1889-1894.
PMID: 35319787
No abstract available.
9.
Arney J, Gray C, Clark J, Smith D, Swank A, Matlock D, et al.
PLoS One
. 2022 Feb;
17(2):e0263874.
PMID: 35180233
Advanced Liver Disease (AdvLD) is common, morbid, and associated with high likelihood of death. Patients may not fully understand their prognosis and are often unprepared for the course of illness....
10.
Shoemaker E, Dale K, Cohn D, Kelly M, Zoerhoff K, Batcho W, et al.
PLoS One
. 2019 Dec;
14(12):e0224925.
PMID: 31856174
Background: Delivery of preventive chemotherapy (PC) through mass drug administration (MDA) is used to control or eliminate five of the most common neglected tropical diseases (NTDs). The success of an...